FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to a novel macrocyclic compound of general formula
,
possessing an inhibiting activity with respect to histone deacetylases (HDAC), a compound-containing pharmaceutical composition, and a method, applied for the treatment of diseases with compound application.
EFFECT: obtaining the compound, possessing an inhibiting activity with respect to histone deacetylases.
11 cl, 3 tbl, 9 dwg, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS FOR USING IT | 2006 |
|
RU2448703C2 |
| METALLOPORPHYRIN TREATMENT OF NEUROLOGICAL DISEASES | 2012 |
|
RU2623207C2 |
| CHIRAL DIARYL MACROCYCLES AND USE THEREOF | 2016 |
|
RU2728579C2 |
| N1-(4-(5-(CYCLOPROPYLMETHYL)-1-METHYL-1H-PYRAZOLE-4-YL)PYRIDINE-2-YL)CYCLOHEXANE-1,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF CK1 AND/OR IRAK1 FOR THE TREATMENT OF CANCER | 2018 |
|
RU2761457C2 |
| AMYLOID-BINDING AGENTS | 2010 |
|
RU2517174C2 |
| CAFFEIC ACID BIOLOGICALLY AVAILABLE FOR ORAL USE, ASSOCIATED WITH ANTITUMOUR MEDICINAL AGENTS | 2007 |
|
RU2456265C2 |
| COMBINATION THERAPY USING DIARYL MACROCYCLIC COMPOUNDS | 2018 |
|
RU2784853C2 |
| CFTR REGULATORS AND METHODS FOR USE THEREOF | 2016 |
|
RU2742934C2 |
| LOW-MOLECULAR INHIBITORS OF N-TERMINUS ACTIVATION OF ANDROGEN RECEPTOR | 2009 |
|
RU2519948C2 |
| OPHTHALMIC PHARMACEUTICAL COMPOSITIONS | 2018 |
|
RU2818087C2 |
